期刊
FRONTIERS IN PSYCHIATRY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fpsyt.2020.554899
关键词
duloxetine; clinical conditions; efficacy; safety; tolerability
类别
资金
- Foundation for Science and Technology (FCT, Fundacao para a Ciencia e Tecnologia) [SFRH/BD/135623/2018]
- Fundacion Tatiana Perez de Guzmanel Bueno
- Carlos III Health Institute (ISCIII, Instituto Carlos III) [P16/00405]
- Spanish Foundation of Rare Diseases (FEDER, Fundacion Espanola de Enfermedades Raras)
- Fundação para a Ciência e a Tecnologia [SFRH/BD/135623/2018] Funding Source: FCT
Duloxetine is a serotonin-norepinephrine reuptake inhibitor approved for the treatment of patients affected by major depressive disorder (MDD), generalized anxiety disorder (GAD), neuropathic pain (NP), fibromyalgia (FMS), and stress incontinence urinary (SUI). These conditions share parallel pathophysiological pathways, and duloxetine treatment might be an effective and safe alternative. Thus, a systematic review was conducted following the 2009 Preferred Reporting Items (PRISMA) recommendations and Joanna Briggs Institute Critical (JBI) Appraisals guidelines. Eighty-five studies focused on efficacy, safety, and tolerability of duloxetine were included in our systematic review. Studies were subdivided by clinical condition and evaluated individually. Thus, 32 studies of MDD, 11 studies of GAD, 19 studies of NP, 9 studies of FMS, and 14 studies of SUI demonstrated that the measured outcomes indicate the suitability of duloxetine in the treatment of these clinical conditions. This systematic review confirms that the dual mechanism of duloxetine benefits the treatment of comorbid clinical conditions, and supports the efficacy, safety, and tolerability of duloxetine in short- and long-term treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据